Opicapone’s domestic launch time and interpretation of the latest policies

Opicapone (Opicapone) is an oral peripheral COMT inhibitor for Parkinson's disease. It is mainly used to improve the "on--off" fluctuations in levodopa treatment. At present, Opicapone has not been officially approved for marketing in China, so patients cannot purchase it directly in domestic hospitals or pharmacies. For patients in need of medicine, they can only obtain the medicine through overseas channels, such as through international medical institutions or legal cross-border drug purchase platforms.

In overseas markets, Opicapone has been approved by the European Medicines Agency (EMA) to assist levodopa/carbidopa in the treatment of motor fluctuations in patients with Parkinson's disease. The price of the original medicine is relatively high. Taking the European version as an example, each box sells for about more than 2,000 yuan. Since it is not currently on the market in China and there are no official generic drugs to choose from, patients who purchase drugs through overseas channels need to pay attention to drug authenticity and transportation safety issues.

In terms of policy, because Opicapone has not been approved in China, the national drug regulatory authorities have not included it in the medical insurance reimbursement system, and there are no import restrictions or special approval guidelines for the drug. Therefore, domestic patients can only rely on overseas purchases, but they must follow relevant cross-border drug purchase and drug import policies to avoid illegal risks. At the same time, when prescribing a treatment plan, doctors also need to carefully evaluate the safety and feasibility of the patient's medication based on the actual clinical situation.

In the future, with the increasing demand for Parkinson's disease medication and the accumulation of clinical data, the possibility of Opicapone being launched in China is gradually increasing. Once approved for marketing, it is expected to have the opportunity to be included in the medical insurance system, thereby reducing the financial burden on patients and improving the management of motor symptoms in patients with Parkinson's disease. While patients are currently paying attention to overseas drug purchase information, they should also pay close attention to the latest developments in domestic approvals and medical insurance policies in order to obtain safe and compliant medication routes in a timely manner.

Reference materials:https://www.drugs.com/